BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FlowCardia, Inc. Announces 510(k) Clearance For The CROSSER(TM) 14 Chronic Total Occlusion Recanalization System


1/23/2007 9:47:56 AM

SUNNYVALE, Calif., Jan. 23 /PRNewswire/ -- FlowCardia, Inc., a medical device company developing endovascular devices for coronary and peripheral chronic total occlusion (CTO) recanalization, announced FDA 510(k) clearance of the CROSSER(TM) 14 CTO Recanalization System. The CROSSER 14 is designed to facilitate the placement of guidewires beyond CTOs in coronary arteries.

The CROSSER 14 is an endovascular catheter that is delivered using standard guidewires to the site of a chronic total occlusion in the coronary arteries. The CROSSER utilizes high-frequency vibration to facilitate guidewire crossing of CTOs allowing for subsequent balloon angioplasty and stent placement. For many patients, this cath-lab based, minimally invasive approach to CTO recanalization can eliminate the need for potentially traumatic Coronary Artery Bypass Graft (CABG) surgery.

The CROSSER 14 clearance follows the completion of the U.S. FACTOR (FlowCardia's Approach to Chronic Total Occlusion Recanalization) clinical study. FlowCardia's 19 hospital, 125 patient pivotal study successfully assessed the safety and efficacy of the CROSSER Catheter in chronically occluded coronary arteries.

Wick Goodspeed, President and CEO of FlowCardia said, "The CROSSER 14 Catheter represents a major milestone for FlowCardia in the U.S. market. With more coronary and peripheral devices in the immediate pipeline, we hope to give all CTO patients a safe and effective, minimally invasive, therapeutic option."

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture safe and effective, endovascular CTO recanalization systems. Additional information is available on the Company's new Web Site at www.flowcardia.com.

CONTACT: Mark Page Director, Marketing FlowCardia, Inc. 408-617-0352 ext. 301

Source: FlowCardia, Inc.

>>> Discuss This Story



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES